Efficiently screening and analyzing antibody discovery is crucial for reducing time and costs in antibody drug development. Traditional hybridoma technology faces challenges like long cycles, limited diversity, and inadequate functional analysis, hindering progress. The AI nanobiochip technology in the Light Workbench can rapidly separate, analyze, culture, and export tens of thousands of single cells simultaneously, completing positive plasma cell screening in one day.